Natriuretic peptides in cardiovascular diseases |
| |
| Authors: | Mariusz Piechota Maciej Banach Anna Jacoń Jacek Rysz |
| |
| Affiliation: | (1) Department of Anaesthesiology and Intensive Care Unit, Boleslaw Szarecki, University Hospital No. 5 in Łódź, Medical University in Łódź, Łódź, Poland;(2) Department Cardiology, 1st Chair of Cardiology and Cardiac Surgery, University Hospital No. 3 in Łódź, Medical University in Łódź, Łódź, Poland;(3) Department of Health Protection Policy, Medical University of Łódź, Łódź, Poland;(4) 2nd Department of Family Medicine, University Hospital No. 2 in Łódź, Medical University in Łódź, Łódź, Poland;(5) Department of Cardiology, Medical University of Łódź, Sterlinga 1/3, 91-425 Łódź, Poland |
| |
| Abstract: | The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin. The activities of natriuretic peptides and endothelins are strictly associated with each other. ANP and BNP inhibit endothelin-1 (ET-1) production. ET-1 stimulates natriuretic peptide synthesis. All natriuretic peptides are synthesized from polypeptide precursors. Changes in natriuretic peptides and endothelin release were observed in many cardiovascular diseases: e.g. chronic heart failure, left ventricular dysfunction and coronary artery disease. |
| |
| Keywords: | Atrial natriuretic peptide Brain natriuretic peptide C-type natriuretic peptide Dendroaspis natriuretic peptide Urodilatin Endothelin-1 |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
